Researchers Identify a Potential Natural Alternative to Ozempic

Quick Summary: My cousin Imran mentioned at a family dinner that he’s a few months into Ozempic and still hasn’t shaken the nausea, which sent me looking for something better than the usual “natural alternative” marketing. What I found instead was a legitimate Stanford study describing a peptide the human body already makes, with real promise but a timeline nowhere close to today.

Introduction

A natural alternative to Ozempic isn’t something I seriously expected to explore, as I had already written a lot about the side effects of this drug. Then my cousin Imran himself said the same thing, almost cursory, at a family dinner. He had been on Ozempic for a few months, losing weight, but the nausea hadn’t subsided as much as he had hoped. I didn’t have any best answer for him other than “give me more time or talk to your GP,” and that bothered me more than expected.

About a week later, a Stanford study came to my feed, and it struck me as if headlines for natural alternative to Ozempic are now rare. By then, I had seen hundreds of similar headlines, almost all of which were recycling the same few supplement ingredients with far more confidence than the actual evidence.

Why I Went Looking for Something Real to Tell Imran

I’ll be upfront about my starting scepticism. After spending time documenting Ozempic’s undisclosed side effects and the gap between what patients were told and what they actually experienced, I’d built up a fairly low tolerance for “natural Ozempic alternative” headlines. Almost all of them turn out to be berberine supplements, specific teas, or fibre blends, genuinely fine for general health but nowhere near capable of replicating what a GLP-1 drug actually does in the body.

Imran’s experience wasn’t unusual, either. Gastrointestinal side effects like nausea and constipation are widely reported among people using GLP-1 medications, common enough that they’re listed prominently in the medication’s own patient information ^[1]. Knowing that made his frustration feel less like bad luck and more like a fairly predictable part of the current treatment landscape. He’d mentioned trying smaller portions and eating more slowly, both things his GP had suggested, and while they’d helped slightly, the nausea hadn’t gone away the way he’d been told it often does after the first couple of months.

What made this particular study different became clear within the first few paragraphs. It wasn’t a supplement company funding a small, favourable trial. It was Stanford Medicine, publishing in Nature, describing a molecule the human body produces entirely on its own. That distinction, source and rigour, is doing almost all of the work in why I kept reading instead of closing the tab the way I usually would.

What Stanford Researchers Actually Found

BRP: A Peptide the Body Already Produces

The molecule at the centre of the discovery is called BRP, short for BRINP2-related peptide. It’s made of just twelve amino acids, and the genuinely interesting part is that it isn’t synthetic at all. It’s something the human body already produces, quietly, without anyone having identified its specific role in appetite regulation until this study. The name itself comes from its parent molecule, BRINP2, a protein whose fragments had never been properly examined for hormone-like activity before this research looked in that direction.

The research was led by Katrin Svensson at Stanford Medicine, alongside colleagues from UC Berkeley, and published in Nature in March 2025 ^[2]. Discoveries like this tend to take years before their full implications become clear, but the foundational finding itself is solid, peer-reviewed work rather than a preliminary press release dressed up as a breakthrough. It’s also worth noting that the same researchers hold patents related to BRP and have founded a company around it, which doesn’t undermine the science but is worth knowing as context for how this discovery might eventually reach the market, if it does at all.

The AI Tool That Found It

What stood out to me about the discovery process itself was how unconventional it was. Researchers built an AI tool to screen thousands of peptide fragments generated from human prohormones, searching specifically for ones that might function like hormones despite never having been catalogued as such. Out of roughly 2,600 candidate peptides, one made from just twelve amino acids stood out, increasing activity in lab-grown neurons roughly tenfold compared to untreated cells, a far stronger response than most of the other candidates tested, including GLP-1 itself in the same experiment.

That’s a meaningfully different starting point from how most drug discovery works. Instead of starting with a known target and designing something to hit it, researchers let the body’s own biology point toward an answer nobody had properly identified before. I found that framing genuinely compelling, and it’s a large part of why this study held my attention long enough to read the whole thing rather than skimming the headline. Most pharmaceutical research chases a mechanism that’s already understood; this went the other direction entirely, letting computational screening surface something hiding in plain sight inside our own biology the whole time.

Why BRP Might Sidestep Ozempic’s Downsides

The detail that mattered most, especially with Imran’s nausea in mind, was where BRP appears to act compared to where Ozempic acts. Semaglutide, the active ingredient in Ozempic, works on receptors spread across the brain, gut, pancreas, and other tissues, which is exactly why it produces such wide-ranging effects, including the digestive side effects that have generated so much attention and litigation. Those same widespread receptors are also part of why semaglutide produces benefits beyond weight loss, including improvements linked to cardiovascular and kidney health, so the trade-off isn’t as simple as “fewer receptors equals a strictly better drug” — it’s a different balance of effects entirely.

BRP appears to work through what researchers describe as a non-incretin pathway, acting specifically within the hypothalamus, the region of the brain that governs hunger and metabolism, rather than spreading its effects across the digestive system. Svensson described the distinction plainly in Stanford’s own coverage of the research: Ozempic’s broad receptor distribution explains its wide-ranging effects, including slowed digestion, while BRP’s more contained action in animal studies suggests appetite suppression without disrupting the gut in the same way. For Imran, that distinction is the entire appeal in one sentence — the same goal, achieved through a narrower route through the body.

What the Animal Studies Show — and Don’t

In testing on mice and minipigs, a single dose of BRP administered before a meal cut food intake by roughly half within an hour. Obese mice given daily doses over two weeks lost a meaningful amount of weight, almost entirely from fat tissue, while untreated control animals gained weight over the same period. Using minipigs alongside mice is a detail worth noting for anyone familiar with preclinical research, since pig physiology tends to translate to human outcomes more reliably than rodent data alone, which made this particular set of results feel slightly more grounded than a mouse-only study would have.

Just as notably, the treated animals avoided several of the side effects commonly associated with GLP-1 drugs, including nausea, constipation, and muscle loss, the exact list Imran would recognise from his own experience. That’s a genuinely promising signal, though it’s worth being precise about what it does and doesn’t prove. Animal studies regularly show effects that don’t fully translate to humans, and appetite regulation in particular can behave differently across species. Mice and minipigs aren’t small humans, and plenty of compounds that looked remarkable in preclinical testing have produced far more modest, or entirely different, results once trialled in people.

What This Would Mean for Someone Like Imran, If It Pans Out

I mentioned the study to Imran the next time I saw him, and his reaction was closer to cautious curiosity than excitement, which felt like the right response. If a version of BRP eventually works in humans the way it does in animals, the appeal for someone like him is obvious: similar appetite suppression without the nausea that’s made months of treatment harder than it needed to be. He asked, reasonably, whether he should just wait and switch once it’s available — the answer, given the years-long gap ahead, was a fairly firm no.

But that’s a genuinely large “if,” resting on years of research that hasn’t started yet in humans at all. I was careful not to present it to him as anything more solid than an encouraging early signal, because that’s exactly what it is, no more and no less. What I didn’t want to do was hand him false hope dressed up as science, the same thing I’ve criticised in every other “natural Ozempic alternative” headline I’ve picked apart on this site.

The Honest Timeline — Why This Isn’t Available Yet

I want to be direct about something that tends to get glossed over in health journalism generally. BRP has not been tested in humans. It isn’t available for purchase, prescription, or use in any form right now, regardless of what supplement marketing may eventually try to claim by borrowing this research as a hook.

This is genuinely early-stage discovery science. Coming from Stanford and appearing in one of the most rigorous journals in the world makes it far more credible than the typical “natural Ozempic alternative” headline, but credibility of the source doesn’t shorten the years-long process required to move from animal studies to an approved human treatment. Svensson has co-founded a company with plans to begin human trials, though no confirmed timeline has been announced as of the most recent coverage I’ve reviewed. Every prescription drug has to pass through safety testing in healthy volunteers, then efficacy testing in the target population, then larger trials confirming both safety and effectiveness at scale, a process that typically takes years and sometimes over a decade, with plenty of promising early discoveries never making it through to approval at all.

I’ve watched this exact pattern before with other early-stage discoveries that generated genuine excitement and then quietly stalled somewhere in the years-long trial process, and it’s worth keeping that history in mind rather than assuming a strong headline guarantees a strong outcome down the line.

What I Actually Told Imran to Do in the Meantime

My advice to Imran was fairly unglamorous: keep doing what his GP has him doing, keep reporting the nausea at his check-ins rather than tolerating it silently, and don’t let a study that’s years from human trials change his current treatment plan. I’ve already covered the wider landscape of GLP-1 medications in detail elsewhere on this site, and that remains the relevant comparison point for anyone making a real decision today, not speculative future research. He took that fairly well, though he did admit part of him had hoped I’d tell him something more actionable than “wait.”

I did mention a few things that have modest, genuine research support for encouraging the body’s own GLP-1 activity — adequate protein intake, soluble fibre, regular activity, and consistent sleep all play a supporting role, though none come close to replicating what a prescription GLP-1 medication actually does. Imran already eats reasonably well, so this wasn’t a dramatic suggestion, more a case of tightening a few habits that were already mostly in place. For anyone earlier in that process, looking at specific whole foods that support weight management alongside medical treatment is a reasonable, low-risk place to start, and it’s the kind of change worth making regardless of whether a future treatment like BRP ever reaches approval.

Conclusion

I went into this research with the expectation of another exaggerated supplement story and I pulled out something that was close to real cautious optimism, which I don’t use often when writing about weight loss trends. Researchers have identified a potential natural alternative to Ozempic that the body already produces, based on legitimate science rather than marketing, and it points to a future where hunger restriction can reduce the side effects that have defined this entire drug category. That future hasn’t come yet, and I’ve told Imran this directly rather than let him go beyond the original location of the research. But for the first time in a long time, it’s a natural alternative to the Ozempic story called “promising” rather than just used for the headline. Whether or not BRP matters to people like Imran is a question that is really years away, and the most honest thing I can do is to do that, rather than exaggerate it more than it currently is.

Medical Disclaimer: This article is based on publicly available research, including a study published in Nature in March 2025. It is not medical advice. BRP has not been tested in humans, is not currently approved or available for use, and should not be confused with any product marketed using this research. If you are considering Ozempic or any weight loss medication, please consult your GP or a qualified healthcare professional.

Frequently Asked Questions

Written by

Faizan Ahmed

"I am a health content writer who started this journey the same way many readers arrive here — searching for clear, honest answers at the wrong hour, and finding content that was either too complicated or too vague to help. Pure Vitality Tips was built out of that experience. Every article published here is researched first — drawing from peer-reviewed studies, WHO, CDC, NHS, NIH, and leading clinical journals. I am not a doctor, but I take the responsibility of writing about health seriously — because I know first-hand how much accurate information matters."

More about Faizan Ahmed →